Peer-reviewedLicence not statedThe Lancet
[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
28 affiliations
- 1Department of Medical Oncology, Hôpital Édouard Herriot, Lyon, France
- 2Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 3Department of Nuclear Medicine, Centre Hospitalier Universitaire de Nantes, Nantes, France
- 4Department of Nuclear Medicine, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier University, Montpellier, France
- 5Department of Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación IIS Imas12, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
- 6Department of Medical Oncology, Institut Català d'Oncologia, Barcelona, Spain
- 7Department of Molecular Radiotherapy, Curanosticum Wiesbaden-Frankfurt, Wiesbaden, Germany
- 8Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands
- 9Department of Cardiology and Internal Medicine, University of Warmia and Mazury, Olsztyn and GAMMED Centrum Diagnostyczno-Lecznicze, Warsaw, Poland
- 10Department of Gastroenterology, King's College Hospital, London, UK
- 11Department of Pancreatology and Digestive Oncology, Université Paris-Cité, Hôpital Beaujon (AP-HP), Clichy, France
- 12Radiometabolic Therapy Unit, Division of Nuclear Medicine, Istituto Europeo di Oncologia IRCCS, Milan, Italy
- 13Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, Germany
- 14Department of Internal Medicine, Gastroenterology and Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany
- 15Department Medicine 1, Universitätsklinikum Erlangen and Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
- 16Department of Nuclear Medicine, Université Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France
- 17Department of Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia
- 18Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA
- 19Department of Medical Oncology, Inselspital, Bern, University Hospital, University of Bern, Bern, Switzerland
- 20Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
- 21Department of Gastroenterology and Endocrinology, Universitätsklinikum Gießen und Marburg, Philipps-Universität Marburg, Marburg, Germany
- 22Department of Endocrinology and Nutrition, Hospital Universitari i Politècnic La Fe, Valencia, Spain
- 23Department of Nuclear Medicine, Hospices Civils de Lyon - Hôpital Louis Pradel, Lyon, France
- 24Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, and Neuroendocrine and Endocrine Tumor Translational Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- 25ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft, Dresden, Germany
- 26ITM Oncologics, Garching bei München, Germany
- 27ITM Medical Isotopes, Garching bei München, Germany
- 28Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, and Neuroendocrine and Endocrine Tumor Translational Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: [email protected]
Related
- Recent Advances in the Management of Gastroenteropancreatic Neuroendocrine Tumors
- Conserved neuronal-like and secretory programs define the spatial architecture of gastroenteropancreatic neuroendocrine tumors
- Somatostatin Analogues Do Not Improve Survival in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis with Ki-67 Stratification
- Genomic Landscape of Gastroenteropancreatic Neuroendocrine Neoplasms Using Panel Sequencing
- Incremental value of delayed [⁶⁸Ga]Ga-DOTATATE PET/MR in the detection of liver metastases from gastroenteropancreatic neuroendocrine tumors.
BibTeX
@article{walter2026177luluedotreotide,
title = {{[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial}},
author = {Thomas Walter and Henning Jann and Catherine Ansquer and Emmanuel Deshayes and Rocio García‐Carbonero and Àlex Teulé and Richard P. Baum and Hein Jan Verberne and Jarosław Bogdan Ćwikła and Rajaventhan Srirajaskanthan and Louis de Mestier and Chiara Maria Grana and Andreas Buck and Dieter Hörsch and Marianne Pavel and Lawrence Dierickx and Michael Michael and Jonathan Strosberg and Attila Kollár and Paula Jimenez-Fonseca and Anja Rinke and Maribel Del Olmo-Garcia and Anthime Flaus and Jorge Hernando and Andreas Kluge and Monika Breuninger and Serhii Melnyk and Konstantin Zhernosekov and Jaume Capdevila},
journal = {The Lancet},
year = {2026},
month = jul,
doi = {10.1016/s0140-6736(26)00604-5},
url = {https://doi.org/10.48620/99378},
}
RIS
TY - JOUR
TI - [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
AU - Thomas Walter
AU - Henning Jann
AU - Catherine Ansquer
AU - Emmanuel Deshayes
AU - Rocio García‐Carbonero
AU - Àlex Teulé
AU - Richard P. Baum
AU - Hein Jan Verberne
AU - Jarosław Bogdan Ćwikła
AU - Rajaventhan Srirajaskanthan
AU - Louis de Mestier
AU - Chiara Maria Grana
AU - Andreas Buck
AU - Dieter Hörsch
AU - Marianne Pavel
AU - Lawrence Dierickx
AU - Michael Michael
AU - Jonathan Strosberg
AU - Attila Kollár
AU - Paula Jimenez-Fonseca
AU - Anja Rinke
AU - Maribel Del Olmo-Garcia
AU - Anthime Flaus
AU - Jorge Hernando
AU - Andreas Kluge
AU - Monika Breuninger
AU - Serhii Melnyk
AU - Konstantin Zhernosekov
AU - Jaume Capdevila
PY - 2026
DA - 2026/07/01
JO - The Lancet
DO - 10.1016/s0140-6736(26)00604-5
UR - https://doi.org/10.48620/99378
SN - 0099-5355
SN - 0140-6736
SN - 1474-547X
ER -